Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters: its significance for the mechanism of lipid lowering by clofibrate and related drugs
- PMID: 188431
- DOI: 10.1016/0021-9150(76)90032-0
Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters: its significance for the mechanism of lipid lowering by clofibrate and related drugs
Abstract
The binding of chlorophenoxyisobutyric (CPIB), tibric (TA) and nicotinic (NA) acids and CPIB ethyl ester (Clofibrate), TA and NA isopropyl esters (TAPE and NAPE) to human lipoproteins of low density of different classes (LDL2, LDL1 and VLDL) and high density (HDL) were studied by equilibrium dialysis and Sephadex gel filtration. Clofibrate and TAPE bound strongly to lipoproteins, but their acids, CPIB and TA and also NA and NAPE, did not bind. In the same experimental conditions, Clofibrate and TAPE bound only weakly to human serum albumin (HSA) and CPIB bound to HSA with a Ka of 3.3 X 10(5) M(-1) for 1 site of high affinity. The Clofibrate and TAPE bound to lipoproteins did not dissociate either during dialysis or during filtration on Sephadex G 25. The binding percentage remained constant for all drug concentrations studied, and the molar ratio of bound drug rose linearly with increasing concentrations. This suggests that the interaction may be irreversible, and there is some evidence that binding may induce irreversible changes in the lipoprotein molecules. These results, and those already found in experiments made with three other drugs related to Clofibrate, lead to the proposal that in their interaction with lipoproteins, the phenyl groups are necessary and the esterification is contributory. The possible role of this interaction in the lipid-lowering effect of the drugs is discussed with special reference to their possible implication in lipoprotein synthesis within the intestinal and hepatic cells.
Similar articles
-
Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters.Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):41-3. doi: 10.1177/00359157760690S210. Proc R Soc Med. 1976. PMID: 1019153 Free PMC article. No abstract available.
-
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.Atherosclerosis. 1979 Aug;33(4):457-77. doi: 10.1016/0021-9150(79)90038-8. Atherosclerosis. 1979. PMID: 228684
-
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].Arzneimittelforschung. 1983;33(5):776-9. Arzneimittelforschung. 1983. PMID: 6683558 German.
-
Dietary and drug treatment of primary hyperlipoproteinemia.Ann Intern Med. 1972 Aug;77(2):267-94. doi: 10.7326/0003-4819-77-2-267. Ann Intern Med. 1972. PMID: 4345081 Review. No abstract available.
-
A physician's guide to hyperlipidemia.Mod Concepts Cardiovasc Dis. 1972 Jul;41(7):31-6. Mod Concepts Cardiovasc Dis. 1972. PMID: 4343098 Review. No abstract available.
Cited by
-
Diseases and drug protein binding.Clin Pharmacokinet. 1978 Mar-Apr;3(2):144-54. doi: 10.2165/00003088-197803020-00004. Clin Pharmacokinet. 1978. PMID: 25156 Review.
-
[Drug treatment of primary hyperlipoproteinemia (author's transl)].Klin Wochenschr. 1978 Feb 1;56(3):99-110. doi: 10.1007/BF01478565. Klin Wochenschr. 1978. PMID: 628199 German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources